Axxam and Polyphor Participate in a Research Partnership for the Treatment of Type-2 Diabetes Funded by the EU
Axxam Spa and Polyphor Ltd announced a joint discovery research project for the generation of GLP-1R modulators. The partnership will receive funding from the EU as part of the Eurostars Program aimed at supporting innovation within the European Union.
The two companies will undertake a three-year research project with the objective of identifying and developing different classes of molecules as novel therapeutic agents to modulate the activity of the Glucagon-like-peptide 1 receptor (GLP-1R) for the treatment of Type-2 Diabetes.
Tailored functional assays will be developed to address the different mode of actions offered by the GLP-1R pharmacology like agonists, allosteric modulators as well as molecules reducing receptor desensitization and internalization.
With the advantages given by the combination of these assets, Axxam and Polyphor will probe the GLP-1R for molecules addressing different mechanisms of action, including allosteric modulators or inhibitors for receptor desensitization.
Other news from the department research and development
